1. Erdafitinib for tumors with FGFR3 mutation: A promising targeted therapy
   Jaspreet Kaur et al, 2023, Cancer Research, Statistics, and Treatment CrossRef
2. The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
   Danijel Sikic et al, 2021, Cancer Management and Research CrossRef
3. YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer
   Seung-Woo Baek et al, 2022, eBioMedicine CrossRef
4. The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort
   Tyler J. Nielsen et al, 2023, Cancer Immunology, Immunotherapy CrossRef
5. FGFR3 Mutations in Urothelial Carcinoma: A Single-Center Study Using Next-Generation Sequencing
   Seong Hyeon Yu et al, 2024, Journal of Clinical Medicine CrossRef
6. Decreased expression of SRY-box containing gene 30 is related to malignant phenotypes of human bladder cancer and correlates with poor prognosis
   Yang Liu et al, 2018, BMC Cancer CrossRef
7. Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival
   Francesco Alessandrino et al, 2020, Radiology CrossRef
8. Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study
   Eman E. Dawood et al, 2022, Journal of the Egyptian National Cancer Institute CrossRef
9. Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers
   Milena Matuszczak et al, 2020, International Journal of Molecular Sciences CrossRef
10. Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression
    Cornelia Braicu et al, 2019, Journal of Experimental & Clinical Cancer Research CrossRef
11. A Real-World Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada
    Feras A. Moria et al, 2024, Current Oncology CrossRef
12. FGFR1–4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer
    Joanna Moes-Sosnowska et al, 2022, International Journal of Molecular Sciences CrossRef
13. Cell signaling and epigenetic regulation of nicotine-induced carcinogenesis
    Qi Sun et al, 2024, Environmental Pollution CrossRef
14. Molecular and Immunohistochemical assessment of Fibroblast Growth Factor Receptor 3 (FGFR3) gene as a survival time predictor in bladder cancer patients
    Samah Mamdouh et al, 2023, Open Access Macedonian Journal of Medical Sciences CrossRef
15. miR-24-3p/FGFR3 Signaling as a Novel Axis Is Involved in Epithelial-Mesenchymal Transition and Regulates Lung Adenocarcinoma Progression
    Pengyu Jing et al, 2018, Journal of Immunology Research CrossRef
16. Synthesis and Evaluation of Novel 7 H -pyrrolo-[2,3- d ]pyrimidine Derivatives As Potential Anticancer Agents
    Yi-Min Liu et al, 2019, Future Medicinal Chemistry CrossRef
17. Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
    Peter Ellinghaus et al, 2022, Cells CrossRef
18. Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer
    Edyta Marta Borkowska et al, 2019, Urologic Oncology: Seminars and Original Investigations CrossRef
19. Nicotine upregulates FGFR3 and RB1 expression and promotes non-small cell lung cancer cell proliferation and epithelial-to-mesenchymal transition via downregulation of miR-99b and miR-192
    Xuemei Du et al, 2018, Biomedicine & Pharmacotherapy CrossRef
20. Expression of miR‐100 and miR‐138 as prognostic biomarkers in non‐muscle‐invasive bladder cancer
    Ana Blanca et al, 2019, APMIS CrossRef
21. Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma
    Mehdi Kardoust Parizi et al, 2021, Urologic Oncology: Seminars and Original Investigations CrossRef
22. FGFR3 – a Central Player in Bladder Cancer Pathogenesis?
    Margaret A. Knowles, 2020, Bladder Cancer CrossRef
23. Cancer-Associated Membrane Protein as Targeted Therapy for Bladder Cancer
    Adlina Roslan et al, 2022, Pharmaceutics CrossRef
24. Cancer Genetics and Therapeutic Opportunities in Urologic Practice
    Jacob J. Adashek et al, 2020, Cancers CrossRef
25. Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma
    Ekaterina Blinova et al, 2020, Life CrossRef
26. Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma
    Ekaterina Blinova et al, 2021, International Journal of Molecular Sciences CrossRef
27. FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
    Alec Kacew et al, 2020, Frontiers in Immunology CrossRef